<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940223-2-00086</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The workshop will be held on Wednesday, March 2, 1994, 8 a.m. to 5 p.m. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Discussion of Activities of the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use; Notice of Public Meeting</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice of public meeting. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is announcing a public workshop on the progress of activities associated with the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). The agency will present summary information on guidelines developed as a result of ICH harmonization initiatives and will respond to questions. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The workshop will be held on Wednesday, March 2, 1994, 8 a.m. to 5 p.m. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The workshop will be held in conference rms. O, P, and Q, third floor, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Janet Showalter, Office of Health Affairs (HFY&hyph;50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;1383.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote international harmonization of regulatory requirements. FDA has participated in many meetings designed to enhance harmonization and is committed to seeking scientifically based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify and then reduce differences in technical requirements for drug development. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ICH is concerned with harmonization of technical requirements for the registration of pharmaceutical products among three regions: The European Union, Japan, and the United States. The six ICH sponsors are the European Union, the European Federation of Pharmaceutical Industry Associations, the Japanese Ministry of Health and Welfare, the Japanese Pharmaceutical Manufacturers Association, FDA, and the U.S. Pharmaceutical Manufacturers Association. <!-- PJG 0012 frnewline --> The ICH Steering Committee includes representatives from each of the organizing bodies and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), as well as observers from the World Health Organization, the Canadian Health Protection Branch, and the European Free Trade Area. The ICH Secretariat, which coordinates the preparation of documentation, is provided by IFPMA. <!-- PJG 0012 frnewline --> ICH was organized to provide an opportunity for tripartite harmonization initiatives to be developed with input from regulatory and industry representatives and other interested parties. FDA is committed to ensuring that there is an opportunity for public comment through  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notices on all of the guidelines developed as a result of the ICH harmonization initiatives. A number of ICH draft guidelines will be published soon in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  for public comment.  <!-- PJG 0012 frnewline --> The purpose of this public workshop is to provide an opportunity for the agency to present summary information about these documents and to respond to questions. In addition, general background information on ICH will be provided.  <!-- PJG 0012 frnewline --> This public workshop should be of interest to professional and consumer organizations and to the pharmaceutical industry.  <!-- PJG 0012 frnewline --> The status of the topics under consideration by ICH is as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> ICH Consensus Draft Guidelines (will be published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 -->  soon for public comment) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. Guideline for the Validation of Analytical Procedures <!-- PJG 0012 frnewline --> 2. Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies <!-- PJG 0012 frnewline --> 3. Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies <!-- PJG 0012 frnewline --> 4. Dose Selection for Carcinogenicity Studies of Therapeutic Agents  <!-- PJG 0012 frnewline --> 5. Good Clinical Practices: Addenda on Investigators Brochure and Essential Documents <!-- PJG 0012 frnewline --> 6. Population Exposure to Assess Clinical Safety <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> ICH Draft Guidelines and Texts in Preparation <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7. Impurities in New Drug Substances (guideline) <!-- PJG 0012 frnewline --> 8. Light Stability Testing (guideline) <!-- PJG 0012 frnewline --> 9. Genotoxicity Testing Requirements (guideline) <!-- PJG 0012 frnewline --> 10. Quality of Biotechnology Products: Genetic Stability (guideline) <!-- PJG 0012 frnewline --> 11. Quality of Biotechnology Products: Stability Testing (annex to guideline on stability testing for new drugs and products) <!-- PJG 0012 frnewline --> 12. Clinical Study Reports (proposals for a common format based upon a comparison of current FDA and European Community (EC) requirements) <!-- PJG 0012 frnewline --> 13. Ethnic Factors in the Acceptability of Foreign Data (studies are in progress and a guideline is in preparation)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> ICH Consensus Draft Guidelines (released for public comment in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 -->  of July 9, 1993) <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 14. Dose-Response Information to Support Drug Registration <!-- PJG 0012 frnewline --> 15. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> ICH Harmonised Tripartite Guidelines (released for public comment in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 -->  of April 16, 1993)  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 16. Detection of Toxicity to Reproduction for Medicinal Products  <!-- PJG 0012 frnewline --> 17. Studies in Support of Special Populations: Geriatrics  <!-- PJG 0012 frnewline --> 18. Stability Testing of New Drug Substances and Products  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: February 17, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;4072 Filed 2&hyph;17&hyph;94; 3:38 pm] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            